Summary: RayStation 11b is a treatment planning system used in radiotherapy, particularly for carbon ion and proton therapies. Key evidence highlights its role in dose calculation and risk minimization in brain and head and neck cancers.
RayStation 11b was cleared via the FDA 510(k) pathway on April 15, 2022. It is manufactured by Raysearch Laboratories Ab (Publ) and classified as a Class 2 device.
What It Is
RayStation 11b is a treatment planning system designed for radiotherapy applications, including carbon ion and proton therapies. It facilitates precise dose calculations and treatment planning to optimize therapeutic outcomes.
Clinical Applications
RayStation 11b is commonly used in clinical scenarios involving complex radiotherapy treatments, such as for brain tumors and head and neck cancers. It aids in planning and optimizing radiation doses to minimize risks and enhance treatment efficacy.
Evidence Summary
The available literature includes six studies, comprising various study types such as RCTs and retrospective analyses, published between 2023 and 2024. These studies focus on dose calculation accuracy and treatment planning optimization.
Reported Outcomes
Published studies report that RayStation 11b enhances dose calculation accuracy in carbon ion and proton therapies. It has been shown to improve treatment planning for brain and head and neck cancers, potentially reducing the risk of radiation-induced complications.
Safety Profile
Reported complications include potential inaccuracies in dose delivery due to geometrical errors and the need for precise calibration. However, no significant adverse events were directly attributed to the device in the reviewed studies.
Evidence Limitations
The evidence is limited by the small number of studies and the need for further research to validate findings across diverse patient populations. Additional studies are needed to explore long-term outcomes and safety profiles.
Frequently Asked Questions
What are the clinical indications for RayStation 11b?
RayStation 11b is indicated for use in treatment planning for radiotherapy, particularly in carbon ion and proton therapies for cancers such as brain and head and neck tumors.
What outcomes have been reported in clinical studies?
Clinical studies have reported improved dose calculation accuracy and optimized treatment planning, particularly in reducing risks associated with brain and head and neck cancer therapies.
What complications have been reported?
Safety data from evidence indicate potential complications related to dose delivery inaccuracies and the importance of precise calibration, though no significant adverse events were directly linked to the device.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.
📬 Stay Updated
Get the latest vascular education content delivered to your inbox.